company background image
4594 logo

BrightPath Biotherapeutics TSE:4594 Stock Report

Last Price

JP¥65.00

Market Cap

JP¥4.3b

7D

-3.0%

1Y

-62.4%

Updated

26 Mar, 2024

Data

Company Financials

BrightPath Biotherapeutics Co., Ltd.

TSE:4594 Stock Report

Market Cap: JP¥4.3b

4594 Stock Overview

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan.

4594 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

BrightPath Biotherapeutics Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BrightPath Biotherapeutics
Historical stock prices
Current Share PriceJP¥65.00
52 Week HighJP¥185.00
52 Week LowJP¥64.00
Beta0
1 Month Change-10.96%
3 Month Change-21.69%
1 Year Change-62.43%
3 Year Change-66.67%
5 Year Change-77.97%
Change since IPO-84.38%

Recent News & Updates

Recent updates

Shareholder Returns

4594JP BiotechsJP Market
7D-3.0%-2.0%1.0%
1Y-62.4%-23.2%38.6%

Return vs Industry: 4594 underperformed the JP Biotechs industry which returned -23% over the past year.

Return vs Market: 4594 underperformed the JP Market which returned 38.8% over the past year.

Price Volatility

Is 4594's price volatile compared to industry and market?
4594 volatility
4594 Average Weekly Movement8.8%
Biotechs Industry Average Movement7.8%
Market Average Movement3.9%
10% most volatile stocks in JP Market8.3%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4594's share price has been volatile over the past 3 months.

Volatility Over Time: 4594's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.

About the Company

FoundedEmployeesCEOWebsite
2003n/aKenichi Nagaihttps://www.brightpathbio.com

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers.

BrightPath Biotherapeutics Co., Ltd. Fundamentals Summary

How do BrightPath Biotherapeutics's earnings and revenue compare to its market cap?
4594 fundamental statistics
Market capJP¥4.32b
Earnings (TTM)-JP¥1.87b
Revenue (TTM)JP¥262.00m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4594 income statement (TTM)
RevenueJP¥262.00m
Cost of RevenueJP¥146.00m
Gross ProfitJP¥116.00m
Other ExpensesJP¥1.99b
Earnings-JP¥1.87b

Last Reported Earnings

Dec 31, 2018

Next Earnings Date

May 10, 2024

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did 4594 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.